Alampour-Rajabi Setareh, El Bounkari Omar, Rot Antal, Müller-Newen Gerhard, Bachelerie Françoise, Gawaz Meinrad, Weber Christian, Schober Andreas, Bernhagen Jürgen
*Institute of Biochemistry and Molecular Cell Biology, Institute of Biochemistry and Molecular Biology, and Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Rhine-Westphalia Technical University of Aachen (RWTH), Aachen, Germany; Centre for Immunology and Infection, Department of Biology, University of York, York, United Kingdom; INSERM, Unité Mixte de Recherche-S 996, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, Université Paris-Sud, Clamart, France; Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, University of Tübingen, Tübingen, Germany; Institute for Cardiovascular Prevention, Klinikum der Universität München, and August-Lenz-Stiftung, Ludwig-Maximilians-Universität München, Munich, Germany; **Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; and Deutches Zentrum für Herz-Kreislauf Forschung (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
*Institute of Biochemistry and Molecular Cell Biology, Institute of Biochemistry and Molecular Biology, and Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Rhine-Westphalia Technical University of Aachen (RWTH), Aachen, Germany; Centre for Immunology and Infection, Department of Biology, University of York, York, United Kingdom; INSERM, Unité Mixte de Recherche-S 996, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, Université Paris-Sud, Clamart, France; Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, University of Tübingen, Tübingen, Germany; Institute for Cardiovascular Prevention, Klinikum der Universität München, and August-Lenz-Stiftung, Ludwig-Maximilians-Universität München, Munich, Germany; **Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; and Deutches Zentrum für Herz-Kreislauf Forschung (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
FASEB J. 2015 Nov;29(11):4497-511. doi: 10.1096/fj.15-273904. Epub 2015 Jul 2.
Macrophage migration-inhibitory factor (MIF) is a pleiotropic cytokine with chemokine-like functions and is a mediator in numerous inflammatory conditions. Depending on the context, MIF signals through 1 or more of its receptors cluster of differentiation (CD)74, CXC-motif chemokine receptor (CXCR)2, and CXCR4. In addition, heteromeric receptor complexes have been identified. We characterized the atypical chemokine receptor CXCR7 as a novel receptor for MIF. MIF promoted human CXCR7 internalization up to 40%, peaking at 50-400 nM and 30 min, but CXCR7 internalization by MIF was not dependent on CXCR4. Yet, by coimmunoprecipitation, fluorescence microscopy, and a proximity ligation assay, CXCR7 was found to engage in MIF receptor complexes with CXCR4 and CD74, both after ectopic overexpression and in endogenous conditions in a human B-cell line. Receptor competition binding and coimmunoprecipitation studies combined with sulfo-SBED-biotin-transfer provided evidence for a direct interaction between MIF and CXCR7. Finally, we demonstrated MIF/CXCR7-mediated functional responses. Blockade of CXCR7 suppressed MIF-mediated ERK- and zeta-chain-associated protein kinase (ZAP)-70 activation (from 2.1- to 1.2-fold and from 2.5- to 1.6-fold, respectively) and fully abrogated primary murine B-cell chemotaxis triggered by MIF, but not by CXCL12. B cells from Cxcr7(-/-) mice exhibited an ablated transmigration response to MIF, indicating that CXCR7 is essential for MIF-promoted B-cell migration. Our findings provide biochemical and functional evidence that MIF is an alternative ligand of CXCR7 and suggest a functional role of the MIF-CXCR7 axis in B-lymphocyte migration.
巨噬细胞移动抑制因子(MIF)是一种具有趋化因子样功能的多效细胞因子,是多种炎症状态的介质。根据具体情况,MIF通过其1种或多种受体分化簇(CD)74、CXC基序趋化因子受体(CXCR)2和CXCR4发出信号。此外,还鉴定出了异源受体复合物。我们将非典型趋化因子受体CXCR7鉴定为MIF的一种新型受体。MIF可使人类CXCR7内化高达40%,在50 - 400 nM和30分钟时达到峰值,但MIF介导的CXCR7内化不依赖于CXCR4。然而,通过免疫共沉淀、荧光显微镜和邻近连接分析发现,无论是在异位过表达后还是在人B细胞系的内源性条件下,CXCR7都能与CXCR4和CD74形成MIF受体复合物。受体竞争结合和免疫共沉淀研究结合磺基-SBED-生物素转移为MIF与CXCR7之间的直接相互作用提供了证据。最后,我们证明了MIF/CXCR7介导的功能反应。阻断CXCR7可抑制MIF介导的细胞外信号调节激酶(ERK)和ζ链相关蛋白激酶(ZAP)-70激活(分别从2.1倍降至1.2倍和从2.5倍降至1.6倍),并完全消除MIF触发的原代小鼠B细胞趋化性,但CXCL12触发的趋化性不受影响。来自Cxcr7(-/-)小鼠的B细胞对MIF的迁移反应消失,表明CXCR7对MIF促进的B细胞迁移至关重要。我们的研究结果提供了生化和功能证据,表明MIF是CXCR7的替代配体,并提示MIF-CXCR7轴在B淋巴细胞迁移中具有功能作用。